Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5806699 | 0.94 | CRHR1 (0.40) | CRHR1 | |
| SCHEMBL5055712 | 0.83 | CRHR1 (0.40) | CRHR1 | |
| SCHEMBL5051889 | 0.83 | CRHR1 (0.37) | CRHR1 | |
| SCHEMBL5112568 | 0.81 | CRHR1 (0.43) | CRHR1 | |
| SCHEMBL5111496 | 0.79 | CRHR1 (0.33) | CRHR1 | |
| SCHEMBL5055781 | 0.79 | CRHR1 (0.36) | CRHR1 | |
| SCHEMBL5054205 | 0.79 | CRHR1 (0.39) | CRHR1 | |
| SCHEMBL5055769 | 0.77 | CRHR1 (0.35) | CRHR1 | |
| SCHEMBL5103520 | 0.76 | CRHR1 (0.42) | CRHR1 | |
| SCHEMBL5100161 | 0.76 | CRHR1 (0.47) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446108-B2 | Tri-and tetraaza-acenaphthylen derivatives as CRF receptor antagonists | NEUROCRINE, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-20040198726-A1 | Tri-and tetraaza-acenaphthylen derivatives as crf receptor antagonists | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2004-10-07 | — | — | US | disclosed |
| EP-1392689-A1 | TRI- AND TETRAAZA-ACENAPHTHYLEN DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | Neurocrine Biosciences, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002094826-A1 | TRI-AND TETRAAZA-ACENAPHTHYLEN DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES INC. (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198726-A1 | Tri-and tetraaza-acenaphthylen derivatives as crf receptor antagonists | CRHR1, AGTR1, NPY1R | CRHR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.